We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA commissioner outlines steps to spur biomedical innovation

FDA commissioner outlines steps to spur biomedical innovation

October 6, 2011
CenterWatch Staff

FDA Commissioner Margaret A. Hamburg, M.D., has released a blueprint containing immediate steps that can be taken to drive biomedical innovation, while improving the health of Americans.

Titled "Driving Biomedical Innovation: Initiatives for Improving Products for Patients," the blueprint addresses concerns about the sustainability of the medical product development pipeline, which is slowing down despite record investments in research and development.

"The Obama Administration is committed to encouraging the entrepreneurs and businesses that are modernizing and strengthening our healthcare system," said HHS secretary Kathleen Sebelius. "The innovation blueprint is another part of our effort to help businesses grow and keep Americans healthy."

"America is at an important crossroads, where the science before us presents unprecedented opportunities to create new and better medical products and to promote better health for the public," said Hamburg. "Our innovation blueprint highlights some of the initiatives FDA will be implementing to ensure that these opportunities are translated into safe and effective treatments that can help keep both American patients and American industry healthy and strong."

While the FDA has long been committed to promoting innovation with a number of efforts underway already this year, Dr. Hamburg recognized the need to create an FDA-wide framework to address the changing scientific landscape. This blueprint launches the Innovation Initiative, identifying additional steps the agency can take immediately to address the most pressing concerns facing patients and industry.

The proposals stem from a review of the FDA's current policies and practices, as well as months of meetings with major stakeholders nationwide, including key industry leaders, small biotech, pharmaceutical and medical device company owners, members of the academic community and patient groups.

The blueprint focuses on implementing the following major actions: rebuilding the FDA's small business outreach services; building the infrastructure to drive and support personalized medicine; creating a rapid drug development pathway for important targeted therapies; harnessing the potential of data mining and information sharing while protecting patient privacy; improving consistency and clarity in the medical device review process; training the next generation of innovators and streamlining and reforming FDA regulations.

United States Ethics/Regulatory

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing